GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity

Lindsey Wang; William Wang; David C Kaelber; Rong Xu; Nathan A Berger

doi:10.1001/jamaoncol.2023.5573

GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity

JAMA Oncol. 2024 Feb 1;10(2):256-258. doi: 10.1001/jamaoncol.2023.5573.

Authors

Lindsey Wang¹, William Wang¹, David C Kaelber², Rong Xu^{3

4}, Nathan A Berger^{1

4}

Affiliations

¹ Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio.
² Departments of Internal Medicine, Pediatrics, and Population and Quantitative Health Sciences and the Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio.
³ Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio.
⁴ Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.

No abstract available

Plain language summary

This cohort study compares glucagon-like peptide 1 receptor agonists (GLP-1RAs) with 7 non–GLP-1RA antidiabetics among drug-naive patients with type 2 diabetes.

MeSH terms

Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / epidemiology
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / epidemiology
Glucagon-Like Peptide-1 Receptor / agonists
Glucagon-Like Peptide-1 Receptor Agonists
Humans
Obesity / complications
Obesity / epidemiology
Overweight / complications
Overweight / epidemiology

Substances

Glucagon-Like Peptide-1 Receptor Agonists
Glucagon-Like Peptide-1 Receptor

Plain language summary

MeSH terms

Substances

Grants and funding